Abstract
Live viruses are new strategies using biological agents to treat cancer. The oncolytic virotherapy is currently under preclinical and clinical investigation all over the world. Attenuated Edmonston B measles vaccine strain (MV-Edm) is nonpathogenic and is being used for vaccination. On the other hand, MV-Edm has potent antitumor activity against several human tumors. In the text, we have focus on elucidation and control of the infection step via binding to host receptors and fusion of MV-Edm by the use of molecular virology techniques. Based on our findings, oncolytic measles viruses have been genetically engineered to target tumor cells and then kill them.
